Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUTENSEN-R vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension (FDA-approved indication for the combination product)
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Terminal half-life: cryptenamine 9-10 h, methylothiazide 18-24 h, reserpine 50-100 h (prolonged due to enterohepatic recirculation and tissue binding; accumulation occurs with daily dosing)
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Reserpine is extensively metabolized in the liver via CYP450 enzymes; chlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 59% (cryptenamine), 50% (methylothiazide), 7% (reserpine); Biliary/fecal: 21% (cryptenamine), 48% (methylothiazide), 90% (reserpine)
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Methylothiazide: 65-70% bound to albumin; Reserpine: 95% bound to alpha-1-acid glycoprotein and albumin; Cryptenamine: insufficient data
~20% bound to albumin; minimal binding to other plasma proteins.
Methylothiazide: 0.25-0.3 L/kg (primarily extracellular fluid); Reserpine: 2.5-7 L/kg (extensive tissue binding, especially adipose and brain); Cryptenamine: ~1 L/kg (moderate distribution)
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: methylothiazide 90-100%; reserpine 50-60% (first-pass metabolism); cryptenamine 40-60% (variable first-pass)
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
e GFR 30-50 m L/min: reduce dose by 50%; e GFR <30 m L/min: contraindicated.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh class A: no adjustment; class B or C: contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for use in children.
Not recommended; inadequate safety data.
Initiate therapy at half the standard adult dose (one-half tablet daily) and titrate cautiously due to increased sensitivity to adverse effects.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
Reserpine component: Risk of mental depression, which may be severe and can lead to suicide. Use with caution in patients with history of depression.
None
Monitor for signs of depression; discontinue if depression occurs.,Electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia) with chlorothiazide.,Orthostatic hypotension with reserpine.,Use cautiously in patients with peptic ulcer disease, renal impairment, or hepatic impairment.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Active peptic ulcer,Ulcerative colitis,History of mental depression,Electroshock therapy,Anuria,Hypersensitivity to reserpine, chlorothiazide, or sulfonamide-derived drugs
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-sodium foods to enhance antihypertensive effect. Grapefruit juice may increase hydralazine absorption; limit intake. Alcohol can exacerbate orthostatic hypotension. Maintain adequate potassium intake (bananas, oranges) unless otherwise instructed.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Use of reserpine component may be associated with increased risk of congenital malformations, but data are limited. Second and third trimesters: Reserpine can cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion; hydrochlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, electrolyte imbalances, and volume depletion. Overall, this combination is classified as pregnancy category C (reserpine) and B (hydrochlorothiazide); avoid use in pregnancy unless benefit outweighs risk.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Reserpine is excreted into breast milk and may cause adverse effects in nursing infants (e.g., nasal congestion, respiratory depression, bradycardia). Hydrochlorothiazide is excreted in small amounts; M/P ratio is approximately 0.6. However, thiazides may suppress lactation. Safety not established; use during breastfeeding is not recommended.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Pregnancy may alter pharmacokinetics of both components; volume expansion may reduce hydrochlorothiazide efficacy. Dose adjustments should be individualized based on blood pressure response and electrolyte monitoring. Generally, use lowest effective dose; avoid in severe hypertension or preeclampsia where oral therapy is inadequate.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
DIUTENSEN-R is a fixed-dose combination of reserpine, hydralazine, and hydrochlorothiazide. Monitor for orthostatic hypotension, especially at initiation. Reserpine may cause nasal congestion and depression; avoid in patients with history of depression. Hydralazine can induce lupus-like syndrome; obtain ANA titers if symptoms develop. Hydrochlorothiazide may cause electrolyte disturbances; check serum potassium and magnesium periodically.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed; do not stop abruptly.,Rise slowly from sitting or lying to prevent dizziness.,Report any signs of depression, unusual bruising, or joint pain.,Avoid excessive sunlight; use sunscreen.,Do not take over-the-counter cold medications without consulting your doctor.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUTENSEN-R vs ALDORIL D50, answered by our medical review team.
DIUTENSEN-R is a Antihypertensive Combination that works by DIUTENSEN-R is a combination of reserpine and chlorothiazide. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT), leading to reduced sympathetic tone. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting natriuresis and reducing plasma volume.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUTENSEN-R and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUTENSEN-R is: One tablet orally once daily. Each tablet contains 2.5 mg reserpine and 25 mg chlorthalidone.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUTENSEN-R and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUTENSEN-R is classified as Category C. First trimester: Use of reserpine component may be associated with increased risk of congenital malformations, but data are limited. Second and third trimesters: Reserpine can caus. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.